Perspectives on the oncologist pharmacopœia;Perspectives sur la pharmacopée de l'oncologue

Bulletin du Cancer

Volumn 90, Issue 1, 2003, Pages 25-30

  Lansiaux, Amélie ^a   Bailly, Christian ^a  

^a Laboratoire de Pharmacologie   (France)

Author keywords

Pharmacology; Treatment

Indexed keywords

6 (4 HYDROXYPHENYL) 4 (ALPHA METHYLBENZYLAMINO) 7H PYRROLO[2,3 D]PYRIMIDINE; 6 HYDROXYMETHYLACYLFULVENE; 7 HYDROXYSTAUROSPORINE; AMMINEDICHLORO(2 METHYLPYRIDINE)PLATINUM; BBR 3464; BCR ABL PROTEIN; BORTEZOMIB; CETUXIMAB; CHIMERIC PROTEIN; DIFLOMOTECAN; DNA; DNA TOPOISOMERASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; F 11782; GEFITINIB; IMATINIB; ISIS 3521; IXABEPILONE; J 107080; PLEVITREXED; PROTEASOME; PROTEIN KINASE C; RIBONUCLEOTIDE REDUCTASE; SEMAXANIB; TRABECTEDIN; TUBULIN; UNCLASSIFIED DRUG; VASCULOTROPIN RECEPTOR; XR 11576;

MEDICAL LITERATURE; ONCOLOGY; REVIEW;

ANGIOGENESIS INHIBITORS; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC AGENTS, ALKYLATING; BORONIC ACIDS; DIOXOLES; INDOLES; ISOQUINOLINES; NEOPLASMS; ORGANOPLATINUM COMPOUNDS; PROTEASE INHIBITORS; PYRAZINES; PYRROLES; QUINAZOLINES; SESQUITERPENES; TETRAHYDROISOQUINOLINES;

EID: 0037283184     PISSN: 00074551     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (51)

1. Ray-Coquard I, Blay JY. Targered rrearment of cancers wirh imatinib mesylate (STI571, Gleevec): results of Asco 2002. Bull Cancer 2002; 89: 567-9.
2. McMorris, T.C. Discovery and development of sesquiterpenoid derived hydroxymerhylacylfulvene: a new anticancer drug. BioOrg Med Chem 1999; 7: 881-6.
3. Pierson AS, Gibbs P, Richards J, Russ P, Eckhardt SG, Gonzalez R. A phase II study of irofulven (MGI 114) in patients with stage IV melanoma. Invest New Drugs 2002; 20: 357-62.
4. Berg WJ, Schwartz L, Yu R, Mazumdar M, Motzer RJ. Phase II trial of irofulven (6-hydroxymethylacylfulvene) for patients with advanced renal cell carcinoma. Invest New Drugs 2001; 19: 317-20.
5. Dowell JE, Johnson DH, Rogers JS, Shyr Y, McCullough N, Krozely P, DeVore RF. A phase II trial of 6-hydroxymethylacylfulvene (MGI-114, irofulven) in patients with advanced non-small cell cancer previously treated with chemotherapy. Invest New Drugs 2001; 19: 85-8.
6. Woynarowska BA, Woynarowski JM. Preferential targeting of apoptosis in tumor versus normal cells. Biochim Biophys Acta 2002; 1587: 309-17.
7. Scotto KW. ET-743: more than an innovative mechanism of action. Anticancer Drugs 2002; 13: S3-6.
8. Demetti GD. ET-743: the US experience in satcomas of soft tissues. Anticancer Drugs 2002; 13: S7-9.
9. Laverdiere C, Kolb A, Meyers P, Gorlick R, Maki R, Wexler L, et al. Phase II study of ET-743 in recurrent osteosarcoma. Proc Am Soc Clin Oncol 2002; 21: 383.
10. Brain EG. Safety and efficacy of ET-743: the French experience. Anticancer Drugs 2002; 13: S11-4.
11. Puchalski TA, Ryan DP, Garcia-Carbonero R, Demetri GD, Butkiewicz L, Harmon D, et al. Pharmacokinetics of ecteinascidin 743 administered as a 24-h continuous intravenous infusion to adult patients with soft tissue sarcomas: associations with clinical characteristics, pathophysiological variables and toxicity. Cancer Chemother Pharmacol 2002; 50: 309-19.
12. George S, Maki R, Harmon D, Supko J, Morgan J, Selden M et al. Phase II study of ecteinascidin-743 (ET-743) given by 3-hour iv infusion in patients with soft tissue sarcomas failing prior chemotherapies. Proc Am Soc Clin Oncol 2002; 21: 1630.
13. Dileo P, Casali P, Bacci G, Casanova M, Aglietta M, Ferrari S, et al. Phase II evaluation of 3-hr infusion ET-743 in patients with recurrent sarcomas. Proc Am Soc Clin Oncol 2002; 21: 1628.
14. MacDonald JS. Oxaliplatin: new opportunities for the treatment of gastrointestinal cancer. Cancer Invest 2002; 20: 287-9.
15. Sessa C, Capri G, Gianni L, Peccarori F, Grasselli G, Bauer J, et al. Clinical and pharmacological phase I study with accelerated titration design of a daily times five schedule of BBR3464, a novel cationic triplatinum complex. Ann Oncol 2000; 11: 977-83.
16. Jodrell D, Evans TRJ, Steward W, Cameron D, Prendiville J, Aschele C, et al. Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocatcinoma. Proc Am Ass Cancer Res 2002; 43: 2761.
17. Hay MP. ZD-0473 AstraZeneca. Curr Opin Investig Drugs 2000; 1: 263-6.
18. Tyrrell C, Bullard S, Barber J, Graham J. ZD0473 open-label phase II study in patienrs wirh metastatic hormone-refractory prostare cancer. Proc Am Soc Clin Oncol 2002; 21: 2468.
19. Gore M, Arkinson RJ, Dirix LY, Rischin D, Beale PJ, Harner P, et al. ZD0473 phase II monotherapy trial in second-line ovarian cancer. Proc Am Soc Clin Oncol 2002; 21: 881.
20. Robak T, Kasznicki M. Alkylaring agents and nucleoside analogues in the treatmenr of B cell chronic lymphocytic leukemia. Leukemia 2002; 16: 1015-27.
21. Fung MC, Sakata T. Whar's new in pancreatic cancer trearment? J Hepatobiliary Pancreat Surg 2002; 9: 61-75.
22. Twelves CJ, Cassidy J. Which endpoinrs should we use in evaluating rhe use of novel fluoropyrimidine regimens in colorectal cancer? Br J Cancer 2002; 86: 1670-6.
23. Smirh D, Gallagher N, Garnett S. A phase II/III trial of efficacy and tolerability of ZD9331 vs gemcitabine in pancreatic cancer. Proc Am Soc Clin Oncol 2002; 21: 574.
24. Lansiaux A, Bailly C. Les camptothécines. Bull Cancer (soumis).
25. Bonneterre J, Cottu P, Adenis A, Bonneterre ME, Obach R, Principe P, et al. Phase I rrial of BN80915 administered inrravenously in patients with advanced malignanr tumors. Ann Oncol 2000; 11: 234.
26. Arakawa H, Morita M, Kodera T, Okura A, Ohkubo M, Morishima H, et al. In vivo antitumor activity of a novel indolocarbazole compound, J-107088, on murine and human tumors transplanted into mice. Jpn J Cancer Res 1999; 90: 1163-70.
27. Yoshinari T, Ohkubo M, Fukasawa K, Egashira S, Hara Y, Matsumoto M, et al. Mode of action of a new indolocarbazole anticancer agent, J-107088, targeting topoisomerase I. Cancer Res 1999; 59: 4271-75.
28. Cavazos CM, Keir ST, Yoshinari T, Bigner DD, Friedman HS. Therapeutic activity of the topoisomerase I inhibitor J-107088 [6-N-(1-hydroxymethyla-2-hydroxyl) ethylamino-12,13-dihydro-13-(beta-D-glucopyranosyl)-5H-indolo[2,3-a]- pyrrolo[3,4-c]-carbazole-5,7(6H)-dione]] against pediatric and adult central nervous system tumor xenografts. Cancer Chemother Pharmacol 2001; 48: 250-4.
29. Lewis L, Perez RP, Petros W, Matsumoto M, Natsumeda Y, Rothenberg M. A phase-I study of the novel topoisomerase-I inhibitor J-107088 administered on a multiple-dose schedule. Proc Am Soc Clin Oncol 2000; 19: 688.
30. Peck R. Phase I Trial of J-107088, a novel topoisomerase I inhibitor, administered once every 21 days. Proc Am Soc Clin Oncol 2000; 19:767.
31. Perez R, Hurwitz H, Nahum K, Lee J, Shiba D, Garcia M, et al. Phase II trials of J-107088, a non-camptothecin topoisomerase I inhibitor, in irinotecan naïve/refractory merastatic colorectal cancer. Proc Am Soc Clin Oncol 2002; 21: 632.
32. Komatani H, Kotani H, Hara Y, Nakagawa R, Matsumoro M, Arakawa H, et al. Identification of breast cancet resistant protein/mitoxantrone resistance/placenta-specific, ATP-binding cassette transporter as a transporter of NB- 506 and J-107088, topoisomerase I inhibitors with an indolocarbazole sttucture. Cancer Res 2001; 61: 2827-32.
33. Kruczynski A, Etievant C, Perrin D, Imbett T, Colpaett F, Hill BT. Preclinical antitumour activity of F 11782, a novel dual catalytic inhibitor of topoisomerases. Br J Cancer 2000; 83: 1516-24.
34. Batret JM, Etievant C, Baudouin C, Skov K, Charveron M, Hill BT. F 11782, a novel caralytic inhibitot of topoisomerases I and II, induces atypical, yet cyrotoxic DNA double-sttand breaks in CHO-K1 cells. Anticancer Res 2002; 22: 187-92.
35. Mistry P, Stewart AJ, Dangerfield W, Baker M, Liddle C, Bootle D, et al. In vitto and in vivo charactetization of XR 11576, a novel, orally active, dual inhibitot of topoisomerase I and II. Anticancer Drugs 2002; 13: 15-28.
36. Lavelle F. New taxanes and epothilone derivarives in clinical trials. Bull Cancer 2002; 89: 343-50.
37. L'Allemain G. News about... the proteasome inhibitor PS341. Bull Cancer 2002; 89: 29-30.
38. Schenkein D. Proteasome inhibitors in the treatment or B-cell malignancies. Clin Lymphoma 2002; 3: 49-55.
39. Richardson PG, Barlogie B, Berenson J, Ttaynor A, Singhal S, Jagannath S, et al. Phase II study of the proteasome inhibitot PS-341 in multiple myeloma (MM) patients (pts) with relapsed/refractory disease. Proc Am Soc Clin Oncol 2002; 21: 40.
40. Shah MH, Mattin E, Ellison C, Kraut E, Kindler H, Young D, et al. A phase II study of proteasome inhibitor PS-341 in metastatic neuroendocrine tumors. Proc Am Soc Clin Oncol 2002; 21: 111.
41. Chauhan D, Catley L, Hideshima T, Li G, Leblanc R, Gupta D, et al. 2-Methoxyestradiol overcomes drug resistance in multiple myeloma cells. Blood 2002; 100: 2187-94.
42. Swannie HC, Kaye SB. Protein kinase C inhibitors. Curr Oncol Rep 2002; 4: 37-46.
43. Herbst RS, Kies MS. ZD1839 (Iressa™) in non-small cell lung cancer. Oncologist 2002; 7: 9-15.
44. Ranson M. ZD1839 (Iressa™): for more than just non-small cell lung cancer. Oncologist 2002; 7:16-24.
45. Motoyama AB, Hynes NE, Lane HA. The efficacy of ErbB receptor-targeted anticancet therapeutics is influenced by the availability of epidetmal growth factor-telated peptides. Cancer Res 2002; 62: 3151-58.
46. Murren J, Papadimitrakopoulou V, Sizer K, Vaidyanathan S, Ravera C, Abbruzzese J. A phase I dose-escalating study to evaluate the biological activity and pharmacokinetics of PKI166, a novel tyrosine kinase inhibitor, in patients with advanced cancers. Proc Am Soc Clin Oncol 2002; 21: 377.
47. Dumez H, Hoekstra R, Eskens F, Sizer K, Vaidyanathan S, Ravera C, et al. A phase I and pharmacological study of PKI166, an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, administeted orally 3 times a week to patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: 341.
48. Hoekstra R, Dumez H, van Oosterom A, Sizer K, Ravera, Sujata Vaidyanathan C, et al. A phase I and pharmacological study of PKI166, an epidetmal growth factor teceptor (EGFR) tyrosine kinase inhibitor, administeted orally in a two weeks on, rwo weeks off scheme to patients with advanced cancer. Proc Am Soc Clin Oncol 2002; 21: 340.
49. Stopeck A, Sheldon M, Vahedian M, Cropp G, Gosalia R, Hannah A. Results of a phase I dose-escalating study of the antiangiogenic agent, SU5416, in patients with advanced malignancies. Clin Cancer Res 2002; 8: 2798-805.
50. Lara PN, Quinn D, Margolin K, Meyers FJ, Longmate J, Ftankel P, et al. Angiogenesis inhibition in renal cell carcinoma (RCC): a phase II califotnia cancer consortium study of SU5416 + intetfeton with biologic and imaging correlates. Proc Am Soc Clin Oncol 2002; 21: 736.
51. Zahalsky AJ, Wong RJ, Lis E, Hann L, Fleisher M, Shah J, et al. Phase II trial of SU5416 in patients with advanced incurable head and neck cancer. Proc Am Soc Clin Oncol 2002; 21: 902.